Is BLCO or NEOG more profitable?

Neogen has a net margin of -0.91% compared to Bausch + Lomb's net margin of -3.21%. Bausch + Lomb's return on equity of 4.14% beat Neogen's return on equity. Company Net Margins Return on Equity Return on Assets Bausch + Lomb -3.21% 4.14% 1.93% Neogen -0.91% 2.78% 1.74%

Does the media prefer BLCO or NEOG?

In the previous week, Bausch + Lomb had 16 more articles in the media than Neogen. MarketBeat recorded 20 mentions for Bausch + Lomb and 4 mentions for Neogen. Neogen's average media sentiment score of 0.84 beat Bausch + Lomb's score of 0.27 indicating that Neogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Neogen 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NEOG or MMSI?

In the previous week, Merit Medical Systems had 7 more articles in the media than Neogen. MarketBeat recorded 11 mentions for Merit Medical Systems and 4 mentions for Neogen. Neogen's average media sentiment score of 0.84 beat Merit Medical Systems' score of 0.83 indicating that Neogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neogen 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Merit Medical Systems 4 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, NEOG or NVST?

Envista has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neogen $870.40M 2.87 -$7.90M -$0.03 N/A Envista $2.72B 1.67 $47M $0.58 48.65

Is NEOG or NVST more profitable?

Envista has a net margin of 3.33% compared to Neogen's net margin of -0.91%. Envista's return on equity of 7.88% beat Neogen's return on equity. Company Net Margins Return on Equity Return on Assets Neogen -0.91% 2.78% 1.74% Envista 3.33% 7.88% 4.33%

Does the media refer more to NEOG or NVST?

In the previous week, Envista had 14 more articles in the media than Neogen. MarketBeat recorded 18 mentions for Envista and 4 mentions for Neogen. Neogen's average media sentiment score of 0.84 beat Envista's score of 0.69 indicating that Neogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neogen 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Envista 5 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, ICUI or NEOG?

ICU Medical has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than ICU Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ICU Medical $2.23B 2.07 $730K $1.85 99.76 Neogen $870.40M 2.87 -$7.90M -$0.03 N/A

Is ICUI or NEOG more profitable?

ICU Medical has a net margin of 1.39% compared to Neogen's net margin of -0.91%. ICU Medical's return on equity of 7.91% beat Neogen's return on equity. Company Net Margins Return on Equity Return on Assets ICU Medical 1.39% 7.91% 4.17% Neogen -0.91% 2.78% 1.74%

Does the media prefer ICUI or NEOG?

In the previous week, ICU Medical had 24 more articles in the media than Neogen. MarketBeat recorded 28 mentions for ICU Medical and 4 mentions for Neogen. ICU Medical's average media sentiment score of 0.90 beat Neogen's score of 0.84 indicating that ICU Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ICU Medical 13 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neogen 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor XRAY or NEOG?

In the previous week, DENTSPLY SIRONA had 18 more articles in the media than Neogen. MarketBeat recorded 22 mentions for DENTSPLY SIRONA and 4 mentions for Neogen. Neogen's average media sentiment score of 0.84 beat DENTSPLY SIRONA's score of 0.52 indicating that Neogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DENTSPLY SIRONA 7 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Neogen 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Neogen (NEOG) Competitors

$11.47 +0.17 (+1.50%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$11.64 +0.17 (+1.48%)

As of 08/7/2026 07:34 PM Eastern

Compare

NEOG vs. BLCO, MMSI, NVST, ICUI, and XRAY

Should you buy Neogen stock or one of its competitors? MarketBeat compares Neogen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Neogen include Bausch + Lomb (BLCO), Merit Medical Systems (MMSI), Envista (NVST), ICU Medical (ICUI), and DENTSPLY SIRONA (XRAY). These companies are all part of the "healthcare supplies" industry.

How does Neogen compare to Bausch + Lomb?

Bausch + Lomb (NYSE:BLCO) and Neogen (NASDAQ:NEOG) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Bausch + Lomb currently has a consensus target price of $18.75, indicating a potential upside of 12.04%. Neogen has a consensus target price of $11.67, indicating a potential upside of 1.71%. Given Bausch + Lomb's stronger consensus rating and higher probable upside, analysts clearly believe Bausch + Lomb is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	8 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.29
Neogen	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

Bausch + Lomb has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, Neogen has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market.

In the previous week, Bausch + Lomb had 16 more articles in the media than Neogen. MarketBeat recorded 20 mentions for Bausch + Lomb and 4 mentions for Neogen. Neogen's average media sentiment score of 0.84 beat Bausch + Lomb's score of 0.27 indicating that Neogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neogen	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neogen has lower revenue, but higher earnings than Bausch + Lomb. Neogen is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.17	-$360M	-$0.48	N/A
Neogen	$870.40M	2.87	-$7.90M	-$0.03	N/A

Neogen has a net margin of -0.91% compared to Bausch + Lomb's net margin of -3.21%. Bausch + Lomb's return on equity of 4.14% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-3.21%	4.14%	1.93%
Neogen	-0.91%	2.78%	1.74%

11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 96.7% of Neogen shares are owned by institutional investors. 1.5% of Bausch + Lomb shares are owned by insiders. Comparatively, 0.6% of Neogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Bausch + Lomb beats Neogen on 9 of the 16 factors compared between the two stocks.

How does Neogen compare to Merit Medical Systems?

Neogen (NASDAQ:NEOG) and Merit Medical Systems (NASDAQ:MMSI) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

96.7% of Neogen shares are held by institutional investors. Comparatively, 99.7% of Merit Medical Systems shares are held by institutional investors. 0.6% of Neogen shares are held by company insiders. Comparatively, 0.7% of Merit Medical Systems shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Merit Medical Systems had 7 more articles in the media than Neogen. MarketBeat recorded 11 mentions for Merit Medical Systems and 4 mentions for Neogen. Neogen's average media sentiment score of 0.84 beat Merit Medical Systems' score of 0.83 indicating that Neogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neogen	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Merit Medical Systems	4 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Merit Medical Systems has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neogen	$870.40M	2.87	-$7.90M	-$0.03	N/A
Merit Medical Systems	$1.52B	3.51	$128.49M	$2.42	36.79

Neogen presently has a consensus target price of $11.67, suggesting a potential upside of 1.71%. Merit Medical Systems has a consensus target price of $100.30, suggesting a potential upside of 12.65%. Given Merit Medical Systems' stronger consensus rating and higher probable upside, analysts clearly believe Merit Medical Systems is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neogen	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Merit Medical Systems	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Merit Medical Systems has a net margin of 9.22% compared to Neogen's net margin of -0.91%. Merit Medical Systems' return on equity of 13.75% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neogen	-0.91%	2.78%	1.74%
Merit Medical Systems	9.22%	13.75%	8.10%

Neogen has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market. Comparatively, Merit Medical Systems has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market.

Summary

Merit Medical Systems beats Neogen on 14 of the 16 factors compared between the two stocks.

How does Neogen compare to Envista?

Neogen (NASDAQ:NEOG) and Envista (NYSE:NVST) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

In the previous week, Envista had 14 more articles in the media than Neogen. MarketBeat recorded 18 mentions for Envista and 4 mentions for Neogen. Neogen's average media sentiment score of 0.84 beat Envista's score of 0.69 indicating that Neogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neogen	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Envista	5 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.7% of Neogen shares are held by institutional investors. 0.6% of Neogen shares are held by company insiders. Comparatively, 1.0% of Envista shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Envista has a net margin of 3.33% compared to Neogen's net margin of -0.91%. Envista's return on equity of 7.88% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neogen	-0.91%	2.78%	1.74%
Envista	3.33%	7.88%	4.33%

Neogen presently has a consensus target price of $11.67, suggesting a potential upside of 1.71%. Envista has a consensus target price of $29.31, suggesting a potential upside of 3.86%. Given Envista's stronger consensus rating and higher probable upside, analysts clearly believe Envista is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neogen	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Envista	0 Sell rating(s)	10 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38

Neogen has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market. Comparatively, Envista has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

Envista has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neogen	$870.40M	2.87	-$7.90M	-$0.03	N/A
Envista	$2.72B	1.67	$47M	$0.58	48.65

Summary

Envista beats Neogen on 12 of the 16 factors compared between the two stocks.

How does Neogen compare to ICU Medical?

ICU Medical (NASDAQ:ICUI) and Neogen (NASDAQ:NEOG) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

ICU Medical has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Neogen has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market.

96.1% of ICU Medical shares are owned by institutional investors. Comparatively, 96.7% of Neogen shares are owned by institutional investors. 2.1% of ICU Medical shares are owned by company insiders. Comparatively, 0.6% of Neogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, ICU Medical had 24 more articles in the media than Neogen. MarketBeat recorded 28 mentions for ICU Medical and 4 mentions for Neogen. ICU Medical's average media sentiment score of 0.90 beat Neogen's score of 0.84 indicating that ICU Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ICU Medical	13 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neogen	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ICU Medical has a net margin of 1.39% compared to Neogen's net margin of -0.91%. ICU Medical's return on equity of 7.91% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ICU Medical	1.39%	7.91%	4.17%
Neogen	-0.91%	2.78%	1.74%

ICU Medical currently has a consensus target price of $192.80, indicating a potential upside of 4.46%. Neogen has a consensus target price of $11.67, indicating a potential upside of 1.71%. Given ICU Medical's stronger consensus rating and higher possible upside, analysts clearly believe ICU Medical is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ICU Medical	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.89
Neogen	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

ICU Medical has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than ICU Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ICU Medical	$2.23B	2.07	$730K	$1.85	99.76
Neogen	$870.40M	2.87	-$7.90M	-$0.03	N/A

Summary

ICU Medical beats Neogen on 14 of the 17 factors compared between the two stocks.

How does Neogen compare to DENTSPLY SIRONA?

DENTSPLY SIRONA (NASDAQ:XRAY) and Neogen (NASDAQ:NEOG) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Neogen has lower revenue, but higher earnings than DENTSPLY SIRONA. Neogen is trading at a lower price-to-earnings ratio than DENTSPLY SIRONA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DENTSPLY SIRONA	$3.68B	0.66	-$598M	-$2.75	N/A
Neogen	$870.40M	2.87	-$7.90M	-$0.03	N/A

DENTSPLY SIRONA presently has a consensus price target of $13.54, indicating a potential upside of 11.70%. Neogen has a consensus price target of $11.67, indicating a potential upside of 1.71%. Given DENTSPLY SIRONA's higher probable upside, equities analysts plainly believe DENTSPLY SIRONA is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DENTSPLY SIRONA	3 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.00
Neogen	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

In the previous week, DENTSPLY SIRONA had 18 more articles in the media than Neogen. MarketBeat recorded 22 mentions for DENTSPLY SIRONA and 4 mentions for Neogen. Neogen's average media sentiment score of 0.84 beat DENTSPLY SIRONA's score of 0.52 indicating that Neogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DENTSPLY SIRONA	7 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Neogen	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DENTSPLY SIRONA has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market. Comparatively, Neogen has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market.

Neogen has a net margin of -0.91% compared to DENTSPLY SIRONA's net margin of -14.99%. DENTSPLY SIRONA's return on equity of 20.84% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DENTSPLY SIRONA	-14.99%	20.84%	5.32%
Neogen	-0.91%	2.78%	1.74%

95.7% of DENTSPLY SIRONA shares are owned by institutional investors. Comparatively, 96.7% of Neogen shares are owned by institutional investors. 0.5% of DENTSPLY SIRONA shares are owned by company insiders. Comparatively, 0.6% of Neogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Neogen beats DENTSPLY SIRONA on 9 of the 16 factors compared between the two stocks.

Get Neogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEOG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NEOG vs. The Competition

Export

Metric	Neogen	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.50B	$5.86B	$7.02B	$13.01B
Dividend Yield	N/A	1.78%	2.58%	10.20%
P/E Ratio	-382.33	24.26	270.57	25.03
Price / Sales	2.87	68.41	599.42	84.81
Price / Cash	13.60	33.55	28.89	37.44
Price / Book	1.19	6.11	11.21	6.43
Net Income	-$7.90M	$149.01M	$3.45B	$348.10M
7 Day Performance	-4.73%	4.75%	4.67%	4.41%
1 Month Performance	17.64%	0.71%	-1.28%	-1.11%
1 Year Performance	125.79%	4.93%	77.33%	23.99%

Neogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NEOG Neogen	1.7799 of 5 stars	$11.47 +1.5%	$11.67 +1.7%	+125.8%	$2.50B	$870.40M	N/A	2,110	Analyst Upgrade Gap Up
BLCO Bausch + Lomb	3.5245 of 5 stars	$16.79 -0.7%	$18.75 +11.7%	+22.4%	$6.04B	$5.10B	N/A	13,000	News Coverage Analyst Downgrade Analyst Revision
MMSI Merit Medical Systems	3.3511 of 5 stars	$85.53 +0.6%	$100.30 +17.3%	+4.0%	$5.08B	$1.52B	35.34	7,500
NVST Envista	2.3072 of 5 stars	$27.31 flat	$28.62 +4.8%	+39.2%	$4.44B	$2.72B	66.61	12,000	News Coverage Positive News Earnings Report Analyst Forecast
ICUI ICU Medical	2.863 of 5 stars	$172.94 +2.6%	$172.00 -0.5%	+63.5%	$4.21B	$2.16B	93.48	13,000	Trending News Earnings Report Analyst Forecast Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NEOG) was last updated on 8/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neogen (NEOG) Competitors

NEOG vs. BLCO, MMSI, NVST, ICUI, and XRAY

How does Neogen compare to Bausch + Lomb?

Summary

How does Neogen compare to Merit Medical Systems?

Summary

How does Neogen compare to Envista?

Summary

How does Neogen compare to ICU Medical?

Summary

How does Neogen compare to DENTSPLY SIRONA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEOG vs. The Competition

Neogen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neogen (NEOG) Competitors

NEOG vs. BLCO, MMSI, NVST, ICUI, and XRAY

How does Neogen compare to Bausch + Lomb?

Do analysts prefer BLCO or NEOG?

Which has more risk and volatility, BLCO or NEOG?

Does the media prefer BLCO or NEOG?

Which has preferable earnings & valuation, BLCO or NEOG?

Is BLCO or NEOG more profitable?

Do institutionals and insiders believe in BLCO or NEOG?

Summary

How does Neogen compare to Merit Medical Systems?

Do institutionals and insiders have more ownership in NEOG or MMSI?

Does the media prefer NEOG or MMSI?

Which has better earnings and valuation, NEOG or MMSI?

Do analysts recommend NEOG or MMSI?

Is NEOG or MMSI more profitable?

Which has more risk & volatility, NEOG or MMSI?

Summary

How does Neogen compare to Envista?

Does the media refer more to NEOG or NVST?

Do insiders & institutionals believe in NEOG or NVST?

Is NEOG or NVST more profitable?

Do analysts prefer NEOG or NVST?

Which has more risk & volatility, NEOG or NVST?

Which has better earnings & valuation, NEOG or NVST?

Summary

How does Neogen compare to ICU Medical?

Which has more volatility & risk, ICUI or NEOG?

Do institutionals & insiders believe in ICUI or NEOG?

Does the media prefer ICUI or NEOG?

Is ICUI or NEOG more profitable?

Do analysts recommend ICUI or NEOG?

Which has better earnings & valuation, ICUI or NEOG?

Summary

How does Neogen compare to DENTSPLY SIRONA?

Which has higher valuation & earnings, XRAY or NEOG?

Do analysts recommend XRAY or NEOG?

Does the media favor XRAY or NEOG?

Which has more risk and volatility, XRAY or NEOG?

Is XRAY or NEOG more profitable?

Do insiders & institutionals believe in XRAY or NEOG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEOG vs. The Competition

Neogen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools